Protein Loop Grafting to Construct a Variant of Tissue-type Plasminogen Activator That Binds Platelet Integrin αIIbβ3(*)
暂无分享,去创建一个
[1] D. Cheresh,et al. Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. , 1990, The Journal of biological chemistry.
[2] J. Wells,et al. A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[3] B. Keyt,et al. Making tissue-type plasminogen activator more fibrin specific. , 1993, Protein engineering.
[4] H Bando,et al. Expression in E. coli of finger‐domain lacking tissue‐type plasminogen activator with high fibrin affinity , 1985, FEBS letters.
[5] E. Goldsmith,et al. Serpin-resistant mutants of human tissue-type plasminogen activator , 1989, Nature.
[6] J W Smith,et al. High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Chothia,et al. The structure of protein-protein recognition sites. , 1990, The Journal of biological chemistry.
[8] D. Cheresh,et al. Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. , 1990, The Journal of biological chemistry.
[9] C. Baum,et al. Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[10] E. Haber,et al. Platelet‐Targeted Fibrinolysis Enhances Clot Lysis and Inhibits Platelet Aggregation , 1991, Circulation.
[11] D. Henner,et al. Engineering human prolactin to bind to the human growth hormone receptor. , 1990, Science.
[12] B. Reavy,et al. A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain. , 1988, The Journal of biological chemistry.
[13] E. Mulvihill,et al. Fibrin Affinity and Clearance of t-PA Deletion and Substitution Analogues , 1990, Thrombosis and Haemostasis.
[14] E. Haber,et al. Innovative approaches to plasminogen activator therapy. , 1989, Science.
[15] C. Barbas. Recent advances in phage display. , 1993, Current opinion in biotechnology.
[16] M. Alessi,et al. Fibrinolysis in insulin dependent diabetic patients with or without nephropathy , 1992 .
[17] J. Scott,et al. Searching for peptide ligands with an epitope library. , 1990, Science.
[18] J W Smith,et al. The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. , 1988, The Journal of biological chemistry.
[19] G. Larsen,et al. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains. , 1988, The Journal of biological chemistry.
[20] T. Kunkel. Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[21] P. Pouwels,et al. Involvement of finger domain and kringle 2 domain of tissue‐type plasminogen activator in fibrin binding and stimulation of activity by fibrin. , 1986, The EMBO journal.
[22] J. Sambrook,et al. Variants of human tissue‐type plasminogen activator that lack specific structural domains of the heavy chain. , 1988, The EMBO journal.
[23] Jeffrey W. Smith,et al. The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin , 1990, The Journal of cell biology.
[24] J. Seidman,et al. Construction and expression of a recombinant antibody-targeted plasminogen activator. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[25] E. Madison,et al. Probing structure-function relationships of tissue-type plasminogen activator by oligonucleotide-mediated site-specific mutagenesis. , 1993, Methods in enzymology.
[26] M. Smith,et al. Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template. , 1984, DNA.
[27] Jeffrey W. Smith,et al. A mechanism for divalent cation regulation of beta 3-integrins. , 1994, The Journal of biological chemistry.
[28] E. Goldsmith,et al. Restoration of serine protease-inhibitor interaction by protein engineering. , 1990, The Journal of biological chemistry.
[29] E. Ruoslahti,et al. [27] Arginine-glycine-aspartic acid adhesion receptors , 1987 .
[30] A. V. van Zonneveld,et al. Autonomous functions of structural domains on human tissue-type plasminogen activator. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[31] J. Sambrook,et al. Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor. , 1992, The Journal of biological chemistry.
[32] M. Matsushima,et al. Structure of a Conformationally Constrained Arg-Gly-Asp Sequence Inserted into Human Lysozyme (*) , 1995, The Journal of Biological Chemistry.
[33] P. Hung,et al. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. , 1988, The Journal of biological chemistry.
[34] E. Goldsmith,et al. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[35] N. Go,et al. Tertiary structure of mouse epidermal growth factor determined by two-dimensional 1H NMR. , 1988, Journal of biochemistry.